CALQUENCE▼ (acalabrutinib) resources

CALQUENCE▼
acalabrutinib 100 mg tablets

Calquence Haematology events, resources and support materials for HCPs and patients

Browse our selection of events, resources and support materials to aid in the initiation and maintenance of CALQUENCE therapy.
If you have any questions or need any further support, you can contact one of our team members here

Contact us

Haematology Events

Watch on demand content and register for future Haematology events

Latest chronic lymphocytic leukamia (CLL) news

Catch up on the latest CLL news and perspectives

CALQUENCE▼ (acalabrutinib) clinical support materials

Download materials designed for HCPs to aid the prescribing and management of CALQUENCE

CALQUENCE▼ (acalabrutinib) clinical trial information

Download materials designed for HCPs to aid the prescribing and management of CALQUENCE

CALQUENCE▼ (acalabrutinib) patient support materials

Download materials designed to support your patients experience with CALQUENCE

Join our mailing list and keep in touch

Want to stay up to date on CALQUENCE and receive the latest news and support materials?

Join our mailing list

CLL, chronic lymphocytic leukaemia; NICE, National Institute for Health and Care Excellence; R/R, relapsed/refractory; SMC, Scottish Medicines Consortium.

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

CALQUENCE▼ (acalabrutinib) resources

Calquence Ha
resources and
for HCPs and

Dimensions: iPhone 6/7/8 375 x 667 100% No throttling

HAEMATOLOGY HORIZON

This is a promotional website intended for UK healthcare professionals only. Non healthcare professionals, please visit astrazeneca.co.uk.

Prescribing Information: UK PI

CALQUENCE acalabrutinib 100 mg tablets

CALQUENCE▼ (acalabrutinib) resources

Calquence Haematology events, resources and support materials for HCPs and patients

Contact us

Browse our selection of events, resources and support materials to aid in the initiation and maintenance of CALQUENCE therapy. If you have any questions or need any further support, you can contact one of our team members here

Haematology Events

Watch on demand content and register for future Haematology events

Latest chronic lymphocytic leukamia (CLL) news

Catch up on the latest CLL news and perspectives

CALQUENCE▼ (acalabrutinib) clinical support materials

Download materials designed for HCPs to aid the prescribing and management of CALQUENCE

CALQUENCE▼ (acalabrutinib) clinical trial information

Download materials designed for HCPs to aid the prescribing and management of CALQUENCE

CALQUENCE▼ (acalabrutinib) patient support materials

Download materials designed to support your patients experience with CALQUENCE

Join our mailing list and keep in touch

Join our mailing list

Want to stay up to date on CALQUENCE and receive the latest news and support materials?

CLL, chronic lymphocytic leukaemia; NICE, National Institute for Health and Care Excellence; R/R, relapsed/refractory; SMC, Scottish Medicines Consortium.

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

CALQUENCE▼ (acalabrutinib) resources

CALQUENCE▼ acalabrutinib 100 mg tablets

Calquence Haematology events, resources and support materials for HCPs and patients

Browse our selection of events, resources and support materials to aid in the initiation and maintenance of CALQUENCE therapy.
If you have any questions or need any further support, you can contact one of our team members here.

Contact us

Haematology Events

Watch on demand content and register for future Haematology events

The CLL Exchange: Debating fixed vs continuous chronic lymphocytic leukaemia (CLL) therapies

Discuss/review the merits and challenges of fixed duration vs treat to progression therapy? Find out more from The CLL Exchange host Dr Faye Sharpley along with expert guests Dr Renata Walewska and Dr Satyen Gohil.

Watch now

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukaemia (CLL)

Are you up to date with the range of BTKis available for CLL treatment? Learn more from The CLL Exchange host Dr Faye Sharpley and expert guest Prof Paul Moss.

Watch now

The CLL Exchange: Guidance for managing complex chronic lymphocytic leukaemia (CLL) patients

How do you overcome the challenges posed by complex/refractory CLL patients? Join The CLL Exchange host Dr Faye Sharpley in conversation with expert guests Dr Toby Eyre and Dr Ben Kennedy.

Watch now

The CLL Exchange: Sequencing strategies for your chronic lymphocytic leukaemia (CLL) patients

Are you confident in mapping treatment options effectively to optimise patient outcomes? Join Dr Faye Sharpley with expert guests Dr Dima El-Sharkawi & Dr Ali Rizouni.

Watch now

The CLL Exchange: Navigating the practicalities affecting treatment decisions in CLL

Don't miss Dr Faye Sharpley in conversation with expert guests Dr Kate Williams and Chrissie Kirby for both a Consultant and Clinical Nurse Specialist perspective on making treatment decisions in CLL.

Watch now

The CLL Exchange: Elevating the patient voice through MDT best practice

How can you best utilise your multidisciplinary team and long-term management of your CLL patients? Listen to the conversation between Dr Faye Sharpley, Clinical Nurse Specialist Charlotte Bloodworth and lymphoma/CLL Pharmacist Arjiel Yousif.

Watch now

CALQUENCE▼ (acalabrutinib) National Summit recording: MAIC of acalabrutinib vs zanubrutinib

This video is a recording of Calquence National Summit 2023 with experts Dr. Alan Skarbnik and statistician Miguel Miranda presenting the Match Adjusted Indirect Comparison of acalabrutinib vs zanubrutinib.

Watch now

CALQUENCE▼ (acalabrutinib) National Summit recording: Managing CV side effects while on BTKis for chronic lymphocytic leukaemia (CLL)

This video is a recording of Calquence National Summit 2023 with expert Dr Ben Kennedy on managing cardiovascular side effects while on BTKis for CLL.

Watch now

CALQUENCE▼ (acalabrutinib) National Summit recording: BSH vs German guidelines in chronic lymphocytic leukaemia (CLL)

This video is a recording of Calquence National Summit 2023 with experts Dr Othman Al Sawaf on the German guidelines in CLL and Dr Toby Eyre on BSH guidelines in CLL.

Watch now

Latest chronic lymphocytic leukaemia (CLL) news

Catch up on the latest CLL news and perspectives

EPIC real world data for front-line chronic lymphocytic leukaemia (CLL) patients treated with CALQUENCE▼ (acalabrutinib)

Expert Renata Walewska presents the real-world data of acalabrutinib "EPIC".

Watch now

ELEVATE-TN 6yr data (exploratory analysis) on CALQUENCE▼ (acalabrutinib) long term efficacy and safety

Expert Mark Rutherfy presents ELEVATE-TN 6-year data showing long term efficacy and safety with acalabrutinib.

Watch now

Piers Patten on MAIC of acalabrutinib and zanubrutinib

Expert Piers Patten presents the Match-Adjusted Indirect Comparison of acalabrutinib and zanubrutinib.

Watch now

Piers Patten on ELEVATE TN 5 year data (exploratory analysis)

Expert Piers Patten presents ELEVATE-TN 5-year data showing long term efficacy and safety with acalabrutinib.

Watch now

Piers Patten on acalabrutinib tablet formulation

Expert Piers Patten presents the bioequivalence between tablets and capsules in light of the reformulation change. Tablets can now be used with PPIs!

Watch now

Piers Patten on ELEVATE RR comparing Ibrutinib and acalabrutinib

Expert Piers Patten presents the head to head trial comparing ibrutinib and acalabrutinib.

Watch now

Piers Patten on maintaining the recommended dose of acalabrutinib

Expert Piers Patten discusses management of adverse events with acalabrutinib while maintaining the recommended dose to achieve optimal efficacy.

Watch now

Insights from ASH 2023 podcast - covalent BTK inhibitors in chronic lymphocytic leukemia (CLL)

Dr Mark Rafferty and Dr Matthew Wilson, consultant haematologists at the Beatson West of Scotland Cancer Centre in Glasgow discuss updates to the ALPINE and ELEVATE-TN trials presented at ASH 2023 and the importance of match-adjusted indirect comparisons (MAICs) in the absence of head-to-head data as well as implications for decision making around choice of BTKi in CLL.

Listen now

Insights from ASH 2023 podcast - non-covalent BTK inhibitors in chronic lymphocytic leukemia (CLL)

Dr Mark Rafferty and Dr Matthew Wilson, consultant haematologists at the Beatson West of Scotland Cancer Centre in Glasgow discuss current needs in the double refractory CLL space and review the clinical data presented at ASH on pirtobrutinib - a non-covalent BTK inhibitor.

Listen now

Insights from ASH 2023 podcast - current research landscape in chronic lymphocytic leukemia (CLL)

Dr Mark Rafferty and Dr Matthew Wilson, consultant haematologists at the Beatson West of Scotland Cancer Centre in Glasgow discuss developments in the current research landscape of CLL including dual covalent/noncovalent inhibitors and alternative targeting pathways in relapsed refractory CLL.

Listen now

Insights from ASH 2023 Podcast - FLAIR Study Data

Dr Parag Jasani, consultant haematologist at the Royal Free London and University College Hospital, London and Dr Helen Marr, consultant haematologist from the Freeman hospital in Newcastle discuss updates to the FLAIR study and how these reflect on data updates from GLOW and CAPTIVATE. They also discuss the need durations of ibrutinib and Venetoclax may inform clinical practice in the UK.

Listen now

Insights from ASH 2023 podcast: Unmutated vs Mutated IGVH Patient Outcomes in chronic lymphocytic leukaemia (CLL)

Dr Parag Jasani, consultant haematologist at the Royal Free London and University College Hospital, London and Dr Helen Marr, consultant haematologist from the Freeman hospital in Newcastle discuss the clinical data updates from GLOW, CAPTIVATE, FLAIR and ELEVATE-TN studies with a specific focus on outcomes in mutated vs unmutated IGVH status and the importance of IGVH testing to UK clinical practice.

Listen now

Insights from ASH 2023 podcast - ELEVATE-TN follow-up data (exploratory analysis)

Dr Parag Jasani, consultant haematologist at the Royal Free London and University College Hospital, London and Dr Helen Marr, consultant haematologist from the Freeman hospital in Newcastle discuss the 6-year ELEVATE-TN follow-up data which compares acalabrutinib with or without obinutuzumab with chlorambucil/obinutuzumab chemo-immunotherapy.

Listen now

Insights from ASH 2023 podcast - emerging cellular therapies in chronic lymphocytic leukaemia (CLL)

Dr Parag Jasani, consultant haematologist at the Royal Free London and University College Hospital, London and Dr Helen Marr, consultant haematologist from the Freeman hospital in Newcastle discuss data developments in CAR-T cell therapy for Relapsed/Refractory CLL patients from the TRANSCEND CL-004 study as well as developments in the bi-specific antibody space for CLL.

Listen now

Insights from ASH 2023 podcast - chronic lymphocytic leukemia (CLL) therapy sequence in the UK

Dr Parag Jasani, consultant haematologist at the Royal Free London and University College Hospital, London and Dr Helen Marr, consultant haematologist from the Freeman hospital in Newcastle discuss considerations for potential CLL therapy sequencing in the UK.

Listen now

Match adjusted indirect comparison (MAIC) methodology evaluation video

This video explains how match adjusted indirect treatment comparisons are developed.

Watch now

Karen Stanley on the role of the chronic lymphocytic leukaemia (CLL) nurse in a multidisciplinary team (MDT)

Advanced Nurse Practitioner Karen Stanley from Guys and St. Thomas' Hospital discusses the importance of the CLL nurse within the MDT, and how patient outcomes are improved when Clinical Nurse Specialists are involved in their care (9 minutes).

Watch now

A chronic lymphocytic leukaemia (CLL) patient journey with Lizette Palmer and Marc Auckland

Marc Auckland, CLL patient, and Lizette Palmer, CLL Clinical Nurse Specialist at Oxford University Hospitals NHSFT, discuss Marc's CLL journey from diagnosis through to treatment and beyond. They cover the challenges of living with CLL and the importance of good communication (15 minutes).

Watch now

Karen Stanley on the evolving role of a chronic lymphocytic leukaemia (CLL) nurse

Advanced Nurse Practitioner Karen Stanley from Guys and St. Thomas' Hospital discusses how CLL treatments have changed over the last 40 years, the ever-changing workload of the CLL Clinical Nurse Specialist, and how to help patients with chemo-free treatment choices (5 minutes).

Watch now

CALQUENCE▼ (acalabrutinib) clinical support materials

Download materials designed for HCPs to aid the prescribing and management of CALQUENCE

CALQUENCE▼ (acalabrutinib) mode of action (MoA) video

This animation describes the mode of action of acalabrutinib.

Watch now

CALQUENCE▼ (acalabrutinib) NICE reimbursement

An algorithm detailing the NICE reimbursement criteria for CALQUENCE in previously untreated and previously treated CLL.

View now

CALQUENCE▼ Therapy Management Guide

Developed in conjunction with Consultants and Specialist Nurses in CLL, this guide outlines best practice and guidance for managing patients who are receiving CALQUENCE for CLL.

View now

CALQUENCE▼ (acalabrutinib) Scottish Medicines Consortium (SMC) acceptance

An algorithm detailing the SMC acceptance criteria for CALQUENCE in previously untreated and previously treated CLL.

View now

CALQUENCE▼ (acalabrutinib) clinical trial information

Download materials designed for HCPs to aid the prescribing and management of CALQUENCE

ELEVATE-TN clinical trial summary

A summary of the ELEVATE-TN trial, including 6-year follow-up data: CALQUENCE with or without obinutuzumab vs. chlorambucil plus obinutuzumab for treatment-naïve CLL.

View now

ELEVATE-RR summary: CALQUENCE▼ (acalabrutinib) vs Ibrutinib

A summary of the ELEVATE-R/R trial: Calquence vs. Ibrutinib in previously treated CLL.

View now

EPIC study: CALQUENCE▼ (acalabrutinib) in chronic lymphocytic leukaemia (CLL) real world data

A summary of the outcomes of EPIC, a real world observational study for front-line CLL patients treated with acalabrutinib via the early access programme (interim analysis).

View now

ASCEND clinical trial summary

A summary of the ASCEND trial: CALQUENCE vs. Ixekatinib plus rituximab or bendamustine plus rituximab in relapsed or refractory CLL.

View now

CALQUENCE▼ (acalabrutinib) patient support materials

Download materials designed to support your patients experience with CALQUENCE

CALQUENCE▼ (acalabrutinib) chronic lymphocytic leukaemia (CLL) Patient Information Booklet

Patient information booklet for patients prescribed CALQUENCE providing helpful information about CLL and CALQUENCE.

Download

Join our mailing list and keep in touch

Want to stay up to date on CALQUENCE and receive the latest news and support materials?

Join our mailing list

CLL, chronic lymphocytic leukaemia; NICE, National Institute for Health and Care Excellence; R/R, relapsed/refractory; SMC, Scottish Medicines Consortium.

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/
Adverse events should also be reported to AstraZeneca by visiting contactanmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

CALQUENCE® Patient Support Program

Calquence hematology/oncology clinical trial support services

Download Calquence hematology/oncology clinical trial support services

Hematology Events

Medication-induced neutropenia

Medication-induced thrombocytopenia

Step 1a: Exchange Targeted Trial Information Between Sponsor and Site

Step 1a: Exchange Targeted Trial Information Between Sponsor and Site

Step 1b: Exchange Standard Trial Information Between Sponsor and Site

Step 1b: Exchange Standard Trial Information Between Sponsor and Site

Step 2a: Exchange Patient Information Between Sponsor and Site

Step 2a: Exchange Patient Information Between Sponsor and Site

Step 2b: Exchange Patient Information Between Sponsor and Site

Step 2b: Exchange Patient Information Between Sponsor and Site

CALQUENCE® 30 qualification and training (Accessing Calquence hematology/oncology clinical trial support services qualification & training)

CALQUENCE® 30 qualification and training (Accessing Calquence hematology/oncology clinical trial support services qualification & training)

CALQUENCE® 30 qualification and training (Accessing Calquence hematology/oncology clinical trial support services qualification & training)

CALQUENCE® 30 qualification and training (Accessing Calquence hematology/oncology clinical trial support services qualification & training)

Lesion-directed hematologic malignancy (Calquence)

Step 1: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 1: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 2: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 2: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 3: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 3: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 4: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 4: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 5: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 5: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 6: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 6: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 7: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 7: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 8: Complete Calquence hematology/oncology clinical trial support services qualification & training

Step 8: Complete Calquence hematology/oncology clinical trial support services qualification & training

CALQUENCE® 30 qualification (Accessing Calquence hematology/oncology clinical trial support services)

CALQUENCE® 30 qualification (Accessing Calquence hematology/oncology clinical trial support services)

CALQUENCE® 30 qualification (Accessing Calquence hematology/oncology clinical trial support services)

CALQUENCE® 30 qualification (Accessing Calquence hematology/oncology clinical trial support services)

CALQUENCE®

CALQUENCE®

CALQUENCE® 30 qualification (Accessing Calquence hematology/oncology clinical trial support services)

CALQUENCE® 30 qualification (Accessing Calquence hematology/oncology clinical trial support services)

Accessing Calquence hematology/oncology clinical trial support services

Download Calquence hematology/oncology clinical trial support services

Accessing Calquence hematology/oncology clinical trial support services

Download Calquence hematology/oncology clinical trial support services

Accessing Calquence hematology/oncology clinical trial support services

Download Calquence hematology/oncology clinical trial support services

Accessing Calquence hematology/oncology clinical trial support services

Download Calquence hematology/oncology clinical trial support services

Accessing Calquence hematology/oncology clinical trial support services

Download Calquence hematology/oncology clinical trial support services

CALQUENCE® 30 qualification (Accessing Calquence hematology/oncology clinical trial support services)

CALQUENCE® 30 qualification (Accessing Calquence hematology/oncology clinical trial support services)

CALQUENCE®
acalabrutinib 100 mg tablets

The CLL Exchange: Debating fixed vs continuous chronic lymphocytic leukaemia (CLL) therapies

Back to Resources



Do you know the merits and challenges of fixed duration vs treat to progression therapy? Find out more from The CLL Exchange host Dr Faye Sharpley along with expert guests Dr Renata Walewska and Dr Satyen Gohil.

Found this useful? You might also be interested in:

Watch now



Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

The CLL Exchange: Debating fixed vs continuous chronic lymphocytic leukaemia (CLL) therapies

Back to Resources

Do you know the merits and challenges of fixed duration vs treat to progression therapy? Find out more from The CLL Exchange host Dr Faye Sharpley along with expert guests Dr Renata Walewska and Dr Satyen Gohil.

Found this useful? You might also be interested in:

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

The CLL Exchange: Guidance for managing complex chronic lymphocytic leukaemia (CLL) patients

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

CALQUENCE®
acalabrutinib 100 mg tablets

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Back to Resources

Are you up to date with the range of BTKis available for CLL treatment? Learn more from The CLL Exchange host Dr Faye Sharpley and expert guest Prof Paul Moss.

Found this useful? You might also be interested in:

Watch now



Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Back to Resources

Are you up to date with the range of BTKis available for CLL treatment? Learn more from The CLL Exchange host Dr Faye Sharpley and expert guest Prof Paul Moss.

Found this useful? You might also be interested in:

The CLL Exchange: Debating fixed vs continuous chronic lymphocytic leukaemia (CLL) therapies

Watch now

The CLL Exchange: Guidance for managing complex chronic lymphocytic leukaemia (CLL) patients

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

CALQUENCE®
acalabrutinib 100 mg tablets

The CLL Exchange: Guidance for managing complex chronic lymphocytic leukaemia (CLL) patients

Back to Resources



How do you overcome the challenges posed by complex/refractory CLL patients? Join The CLL Exchange host Dr Faye Sharpley in conversation with expert guests Dr Toby Eyre and Dr Ben Kennedy.

Found this useful? You might also be interested in:

The CLL Exchange: Debating fixed vs continuous chronic lymphocytic leukaemia (CLL) therapies

Watch now

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

The CLL Exchange: Guidance for managing complex chronic lymphocytic leukaemia (CLL) patients

Back to Resources

How do you overcome the challenges posed by complex/refractory CLL patients? Join The CLL Exchange host Dr Faye Sharpley in conversation with expert guests Dr Toby Eyre and Dr Ben Kennedy.

Found this useful? You might also be interested in:

The CLL Exchange: Debating fixed vs continuous chronic lymphocytic leukaemia (CLL) therapies

Watch now

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

CALQUENCE®
acalabrutinib 100 mg tablets

The CLL Exchange: Sequencing strategies for your chronic lymphocytic leukaemia (CLL) patients

Back to Resources



Are you confident in navigating treatment sequencing effectively to optimise patient outcomes? Join Dr Faye Sharpley with expert guests Dr Dima El-Sharkawi & Dr Ali Rismani.

Found this useful? You might also be interested in:

The CLL Exchange: Debating fixed vs continuous chronic lymphocytic leukaemia (CLL) therapies

Watch now

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

The CLL Exchange: Sequencing strategies for your chronic lymphocytic leukaemia (CLL) patients

Back to Resources

Are you confident in navigating treatment sequencing effectively to optimise patient outcomes? Join Dr Faye Sharpley with expert guests Dr Dima El-Sharkawi & Dr Ali Rismani.

Found this useful? You might also be interested in:

The CLL Exchange: Debating fixed vs continuous chronic lymphocytic leukaemia (CLL) therapies

Watch now

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

CALQUENCE®
acalabrutinib 100 mg tablets

The CLL Exchange: Navigating the practicalities affecting treatment decisions in CLL

Back to Resources



Don't miss Dr Faye Sharpley in conversation with Dr Stella Williams and Chrissie Kirby for both a Consultant and Clinical Nurse Specialist perspective on making treatment decisions in CLL.

Found this useful? You might also be interested in:

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

The CLL Exchange: Sequencing strategies for your chronic lymphocytic leukaemia (CLL) patients

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

The CLL Exchange: Navigating the practicalities affecting treatment decisions in CLL

Back to Resources

Don't miss Dr Faye Sharpley in conversation with Dr Stella Williams and Chrissie Kirby for both a Consultant and Clinical Nurse Specialist perspective on making treatment decisions in CLL.

Found this useful? You might also be interested in:

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

The CLL Exchange: Sequencing strategies for your chronic lymphocytic leukaemia (CLL) patients

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

CALQUENCE®
acalabrutinib 100 mg tablets

The CLL Exchange: Elevating the patient voice through MDT best practice

Back to Resources



How can you best utilise your multidisciplinary team for the long-term management of your CLL patients? Listen to the conversation between Dr Faye Sharpley, Clinical Nurse Specialist Charlotte Bloodworth and Lymphoma/CLL Pharmacist Asjad Yousif

---

Found this useful? You might also be interested in:

The CLL Exchange: Guidance for managing complex chronic lymphocytic leukaemia (CLL) patients

Watch now

The CLL Exchange: Navigating the practicalities affecting treatment decisions in CLL

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

The CLL Exchange: Elevating the patient voice through MDT best practice

Back to Resources

How can you best utilise your multidisciplinary team for the long-term management of your CLL patients? Listen to the conversation between Dr Faye Sharpley, Clinical Nurse Specialist Charlotte Bloodworth and Lymphoma/CLL Pharmacist Asjad Yousif

---

Found this useful? You might also be interested in:

The CLL Exchange: Guidance for managing complex chronic lymphocytic leukaemia (CLL) patients

Watch now

The CLL Exchange: Navigating the practicalities affecting treatment decisions in CLL

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

CALQUENCE▼
acalabrutinib 100 mg tablets

CALQUENCE▼ (acalabrutinib) National Summit recording - MAIC of acalabrutinib vs zanubrutin

Back to Resources

This video is a recording of Calquence National Summit 2023 with experts Pr. Alan Skarbnik and statistician Miguel Miranda presenting the Match Adjusted Indirect Comparison of acalabrutinib vs zanubrutinib.

Found this useful? You might also be interested in:

CALQUENCE▼ (acalabrutinib) National Summit recording: Managing CV side effects while on BTKIs for chronic lymphocytic leukaemia (CLL)

Watch now

CALQUENCE▼ (acalabrutinib) National Summit recording: BSH vs German guidelines in chronic lymphocytic leukaemia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

CALQUENCE▼ (acalabrutinib) National Summit recording - MAIC of acalabrutinib vs zanubrutin

Back to Resources

This video is a recording of Calquence National Summit 2023 with experts Pr. Alan Skarbnik and statistician Miguel Miranda presenting the Match Adjusted Indirect Comparison of acalabrutinib vs zanubrutinib.

Found this useful? You might also be interested in:

CALQUENCE▼ (acalabrutinib) National Summit recording: Managing CV side effects while on BTKIs for chronic lymphocytic leukaemia (CLL)

Watch now

CALQUENCE▼ (acalabrutinib) National Summit recording: BSH vs German guidelines in chronic lymphocytic leukaemia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

CALQUENCE▼
acalabrutinib 100 mg tablets

CALQUENCE▼ (acalabrutinib) National Summit recording: Managing CV side effects while on BTKIs for chronic lymphocytic leukaemia (CLL)

Back to Resources

This video is a recording of Calquence National Summit 2023 with expert Dr Ben Kennedy on managing cardiovascular side effects while on BTKIs for CLL.

Found this useful? You might also be interested in:

CALQUENCE▼ (acalabrutinib) National Summit recording - MAIC of acalabrutinib vs zanubrutin

Watch now

CALQUENCE▼ (acalabrutinib) National Summit recording: BSH vs German guidelines in chronic lymphocytic leukaemia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

CALQUENCE▼ (acalabrutinib) National Summit recording: Managing CV side effects while on BTKIs for chronic lymphocytic leukaemia (CLL)

Back to Resources

This video is a recording of Calquence National Summit 2023 with expert Dr Ben Kennedy on managing cardiovascular side effects while on BTKIs for CLL.

Found this useful? You might also be interested in:

CALQUENCE▼ (acalabrutinib) National Summit recording - MAIC of acalabrutinib vs zanubrutin

Watch now

CALQUENCE▼ (acalabrutinib) National Summit recording: BSH vs German guidelines in chronic lymphocytic leukaemia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

CALQUENCE▼
acalabrutinib 100 mg tablets

CALQUENCE▼ (acalabrutinib) National Summit recording: BSH vs German guidelines in chronic lymphocytic leukaemia (CLL)

Back to Resources

This video is a recording of Calquence National Summit 2023 with experts Dr Othman Al Sawaf on the German guidelines in CLL and Dr Toby Eyre on BSH guidelines in CLL.

Found this useful? You might also be interested in:

CALQUENCE▼ (acalabrutinib) National Summit recording - MAIC of acalabrutinib vs zanubrutin

Watch now

CALQUENCE▼ (acalabrutinib) National Summit recording: Managing CV side effects while on BTKIs for chronic lymphocytic leukaemia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Haematology Events

CALQUENCE▼ (acalabrutinib) National Summit recording: BSH vs German guidelines in chronic lymphocytic leukaemia (CLL)

Back to Resources

This video is a recording of Calquence National Summit 2023 with experts Dr Othman Al Sawaf on the German guidelines in CLL and Dr Toby Eyre on BSH guidelines in CLL.

Found this useful? You might also be interested in:

CALQUENCE▼ (acalabrutinib) National Summit recording - MAIC of acalabrutinib vs zanubrutin

Watch now

CALQUENCE▼ (acalabrutinib) National Summit recording: Managing CV side effects while on BTKIs for chronic lymphocytic leukaemia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE▼
acalabrutinib 100 mg tablets

EPIC real world data for front-line chronic lymphocytic leukaemia (CLL) patients treated with CALQUENCE▼(acalabrutinib)

Back to Resources



Expert Renata Walewska presents the real-world data of acalabrutinib "EPIC".

Found this useful? You might also be interested in:

Watch now



Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

EPIC real world data for front-line chronic lymphocytic leukaemia (CLL) patients treated with CALQUENCE▼(acalabrutinib)

Back to Resources



Expert Renata Walewska presents the real-world data of acalabrutinib "EPIC".

Found this useful? You might also be interested in:

The CLL Exchange: Debating fixed vs continuous chronic lymphocytic leukaemia (CLL) therapies

Watch now

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE▼
acalabrutinib 100 mg tablets

ELEVATE-TN 6yr data (exploratory anaylsis) on CALQUENCE▼(acalabrutinib) long term efficacy and safety

Back to Resources

Expert Mark Rafferty presents ELEVATE TN 6 year data showing long term efficacy and safety with acalabrutinib.

Found this useful? You might also be interested in:

EPIC real world data for front-line chronic lymphocytic leukaemia (CLL) patients treated with CALQUENCE▼(acalabrutinib)

Watch now

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

ELEVATE-TN 6yr data (exploratory anaylsis) on CALQUENCE▼(acalabrutinib) long term efficacy and safety

Back to Resources

Expert Mark Rafferty presents ELEVATE TN 6 year data showing long term efficacy and safety with acalabrutinib.

Found this useful? You might also be interested in:

EPIC real world data for front-line chronic lymphocytic leukaemia (CLL) patients treated with CALQUENCE▼(acalabrutinib)

Watch now

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Piers Patten on MAIC of acalabrutinib and zanubrutinib

Back to Resources



Expert Piers Patten presents the Match Adjusted Indirect Comparison of acalabrutinib and zanubrutinib.

Found this useful? You might also be interested in:

Piers Patten on ELEVATE TN 5 year data (exploratory anaylsis)

Watch now

Match adjusted indirect comparison (MAIC) methodology explanation video

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Piers Patten on MAIC of acalabrutinib and zanubrutinib

Back to Resources

Expert Piers Patten presents the Match Adjusted Indirect Comparison of acalabrutinib and zanubrutinib.

Found this useful? You might also be interested in:



Watch now



Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Piers Patten on ELEVATE TN 5 year data (exploratory anaylsis)

Back to Resources



Expert Piers Patten presents ELEVATE TN 5 year data showing long term efficacy and safety with acalabrutinib.

Found this useful? You might also be interested in:

Piers Patten on MAIC of acalabrutinib and zanubrutinib

Watch now

Piers Patten on ELEVATE RR comparing ibrutinib and acalabrutinib

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Piers Patten on ELEVATE TN 5 year data (exploratory anaylsis)

Back to Resources

Expert Piers Patten presents ELEVATE TN 5 year data showing long term efficacy and safety with acalabrutinib.

Found this useful? You might also be interested in:

Piers Patten on MAIC of acalabrutinib and zanubrutinib

Watch now

Piers Patten on ELEVATE RR comparing ibrutinib and acalabrutinib

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Piers Patten on acalabrutinib tablet formulation

Back to Resources

Expert Piers Patten presents the bioequivalence between tablets and capsules in light of the formulation change. Tablets can now be used with PPIs!

Found this useful? You might also be interested in:

Piers Patten on MAIC of acalabrutinib and zanubrutinib

Watch now

Piers Patten on ELEVATE RR comparing ibrutinib and acalabrutinib

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Piers Patten on acalabrutinib tablet formulation

Back to Resources

Expert Piers Patten presents the bioequivalence between tablets and capsules in light of the formulation change. Tablets can now be used with PPIs!

Found this useful? You might also be interested in:

Piers Patten on MAIC of acalabrutinib and zanubrutinib

Watch now

Piers Patten on ELEVATE RR comparing ibrutinib and acalabrutinib

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Piers Patten on ELEVATE RR comparing ibrutinib and acalabrutinib

Back to Resources



Expert Piers Patten presents the head to head trial comparing ibrutinib and acalabrutinib.

Found this useful? You might also be interested in:

Watch now

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Piers Patten on ELEVATE RR comparing ibrutinib and acalabrutinib

Back to Resources

Expert Piers Patten presents the head to head trial comparing ibrutinib and acalabrutinib.

Found this useful? You might also be interested in:

Watch now

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Piers Patten on maintaining the recommended dose of acalabrutinib

Back to Resources



Expert Piers Patten discusses management of adverse events with acalabrutinib while maintaining the recommended dose to achieve optimal efficacy.

Found this useful? You might also be interested in:

Piers Patten on MAIC of acalabrutinib and zanubrutinib

Watch now

Piers Patten on ELEVATE TN 5 year data (exploratory anaylsis)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Piers Patten on maintaining the recommended dose of acalabrutinib

Back to Resources



Expert Piers Patten discusses management of adverse events with acalabrutinib while maintaining the recommended dose to achieve optimal efficacy.

Found this useful? You might also be interested in:

Piers Patten on MAIC of acalabrutinib and zanubrutinib

Watch now

Piers Patten on ELEVATE TN 5 year data (exploratory anaylsis)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Insights from ASH 2023 podcast - covalent BTK inhibitors in chronic lymphocytic leukamia (CLL)

Back to Resources

Dr Mark Rafferty and Dr Matthew Wilson, consultant haematologists at the Beatson West of Scotland Cancer Centre in Glasgow discuss updates to the ALPINE and ELEVATE-TN studies in CLL presented at ASH 2023 and the importance of match-adjusted indirect comparisons (MAICs) in the absence of head-to head data as well as implications for decision making around choice of BTKi in CLL.

Found this useful? You might also be interested in:

Listen now

Listen now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

Latest CLL News

Insights from ASH 2023 podcast - covalent BTK inhibitors in chronic lymphocytic leukamia (CLL)

Back to Resources

Dr Mark Rafferty and Dr Matthew Wilson, consultant haematologists at the Beatson West of Scotland Cancer Centre in Glasgow discuss updates to the ALPINE and ELEVATE-TN studies in CLL presented at ASH 2023 and the importance of match-adjusted indirect comparisons (MAICs) in the absence of head-to head data as well as implications for decision making around choice of BTKi in CLL.

Found this useful? You might also be interested in:

Insights from ASH 2023 podcast - covalent BTK inhibitors in chronic lymphocytic leukaemia (CLL)

Insights from ASH 2023 podcast - current research landscape in chronic lymphocytic leukamia (CLL)

Listen now

Listen now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Insights from ASH 2023 podcast - non-covalent BTK inhibitors in chronic lymphocytic leukaemia (CLL)

Back to Resources

Dr Mark Rafferty and Dr Matthew Wilson, consultant haematologists at the Beatson West of Scotland Cancer Centre in Glasgow discuss unmet needs in the double refractory CLL space and review the clinical data presented at ASH on pirtobrutinib – a non-covalent BTK inhibitor.

Found this useful? You might also be interested in:

Insights from ASH 2023 podcast - covalent BTK inhibitors in chronic lymphocytic leukamia (CLL)

Listen now

Insights from ASH 2023 podcast - current research landscape in chronic lymphocytic leukamia (CLL)

Listen now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Insights from ASH 2023 podcast - non-covalent BTK inhibitors in chronic lymphocytic leukaemia (CLL)

Back to Resources

Dr Mark Rafferty and Dr Matthew Wilson, consultant haematologists at the Beatson West of Scotland Cancer Centre in Glasgow discuss unmet needs in the double refractory CLL space and review the clinical data presented at ASH on pirtobrutinib – a non-covalent BTK inhibitor.

Found this useful? You might also be interested in:

Insights from ASH 2023 podcast - non-covalent BTK inhibitors in chronic lymphocytic leukamia (CLL)

Insights from ASH 2023 podcast - current research landscape in chronic lymphocytic leukamia (CLL)

Listen now

Listen now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Insights from ASH 2023 podcast - current research landscape in chronic lymphocytic leukamia (CLL)

Back to Resources

Dr Mark Rafferty and Dr Matthew Wilson, consultant haematologists at the Beatson West of Scotland Cancer Centre in Glasgow discuss developments in the current research landscape of CLL including dual covalent/noncovalent inhibitors and alternative targeting pathways in relapsed refractory CLL.

Found this useful? You might also be interested in:

Insights from ASH 2023 podcast - covalent BTK inhibitors in chronic lymphocytic leukamia (CLL)

Listen now

Insights from ASH 2023 podcast - non-covalent BTK inhibitors in chronic lymphocytic leukaemia (CLL)

Listen now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

Latest CLL News

Insights from ASH 2023 podcast - current research landscape in chronic lymphocytic leukamia (CLL)

Back to Resources

Dr Mark Rafferty and Dr Matthew Wilson, consultant haematologists at the Beatson West of Scotland Cancer Centre in Glasgow discuss developments in the current research landscape of CLL including dual covalent/noncovalent inhibitors and alternative targeting pathways in relapsed refractory CLL.

Found this useful? You might also be interested in:

Insights from ASH 2023 podcast - non-covalent BTK inhibitors in chronic lymphocytic leukaemia (CLL)

Listen now

Listen now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

This website has been funded and developed by AstraZeneca

Legal Notice

Privacy Policy

Cookie Policy

May 2025 | GB-65090

© AstraZeneca 2024. All rights reserved.

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Insights from ASH 2023 Podcast - FLAIR Study Data

Back to Resources

Dr Parag Jasani, consultant haematologist at the Royal Free London and University College Hospital, London and Dr Helen Marr, consultant haematologist from the Freeman hospital in Newcastle discuss updates to the FLAIR study as well as reflect on data updates from GLOW and CAPTIVATE and how these fixed durations of Ibrutinib and Venetoclax may inform clinical practice in the UK.

Found this useful? You might also be interested in:

Insights from ASH 2023 podcast: Unmutated vs Mutated IGVH Patient Outcomes in chronic lymphocytic leukaemia (CLL)

Listen now

Insights from ASH 2023 podcast - ELEVATE-TN follow-up data (exploratory analysis)

Listen now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Insights from ASH 2023 Podcast - FLAIR Study Data

Back to Resources

Dr Parag Jasani, consultant haematologist at the Royal Free London and University College Hospital, London and Dr Helen Marr, consultant haematologist from the Freeman hospital in Newcastle discuss updates to the FLAIR study as well as reflect on data updates from GLOW and CAPTIVATE and how these fixed durations of Ibrutinib and Venetoclax may inform clinical practice in the UK.

Found this useful? You might also be interested in:

Listen now

Listen now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Insights from ASH 2023 podcast: Unmutated vs Mutated IGVH Patient Outcomes in chronic lymphocytic leukaemia (CLL)

Back to Resources

Dr Parag Jasani, consultant haematologist at the Royal Free London and University College Hospital, London and Dr Helen Marr, consultant haematologist from the Freeman hospital in Newcastle discuss the clinical data updates from GLOW, CAPTIVATE, FLAIR and ELEVATE-TN studies with a specific focus on outcomes in mutated vs unmutanted IGVH status and the importance of IGVH testing to UK clinical practice.

Found this useful? You might also be interested in:

Insights from ASH 2023 podcast - ELEVATE-TN follow-up data (exploratory analysis)

Listen now

Insights from ASH 2023 Podcast - FLAIR Study Data

Listen now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Insights from ASH 2023 podcast: Unmutated vs Mutated IGVH Patient Outcomes in chronic lymphocytic leukaemia (CLL)

Back to Resources

Dr Parag Jasani, consultant haematologist at the Royal Free London and University College Hospital, London and Dr Helen Marr, consultant haematologist from the Freeman hospital in Newcastle discuss the clinical data updates from GLOW, CAPTIVATE, FLAIR and ELEVATE-TN studies with a specific focus on outcomes in mutated vs unmutanted IGVH status and the importance of IGVH testing to UK clinical practice.

Found this useful? You might also be interested in:

Insights from ASH 2023 Podcast - ELEVATE-TN follow-up data (exploratory analysis)

Listen now

Insights from ASH 2023 Podcast - FLAIR Study Data

Listen now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Match adjusted indirect comparison (MAIC) methodology explanation video

Back to Resources



This video explains how match adjusted indirect treatment comparisons are developed.

Found this useful? You might also be interested in:

Watch now

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Match adjusted indirect comparison (MAIC) methodology explanation video

Back to Resources

This video explains how match adjusted indirect treatment comparisons are developed.

Found this useful? You might also be interested in:

Piers Patten on ELEVATE TN
5 year data (exploratory anaylsis)

Watch now

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Karen Stanley on the role of the chronic lymphocytic leukaemia (CLL) nurse in a multidisciplinary team (MDT)

Back to Resources



Advanced Nurse Practitioner Karen Stanley from Guys and St. Thomas' Hospital discusses the importance of the CLL nurse within the MDT, and how patient outcomes are improved when Clinical Nurse Specialists are involved in their care (9 minutes).

Found this useful? You might also be interested in:

Karen Stanley on the evolving role of a chronic lymphocytic leukaemia (CLL) nurse

Watch now

A chronic lymphocytic leukaemia (CLL) patient journey with Lianne Palmer and Marc Auckland

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Karen Stanley on the role of the chronic lymphocytic leukaemia (CLL) nurse in a multidisciplinary team (MDT)

Back to Resources

Advanced Nurse Practitioner Karen Stanley from Guys and St. Thomas' Hospital discusses the importance of the CLL nurse within the MDT, and how patient outcomes are improved when Clinical Nurse Specialists are involved in their care (9 minutes).

Found this useful? You might also be interested in:

A chronic lymphocytic leukaemia (CLL) nurse

A chronic lymphocytic leukamia (CLL) patient journey with Lianne Palmer and Marc Auckland

Watch now

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

A chronic lymphocytic leukamia (CLL) patient journey with Lianne Palmer and Marc Auckland

Back to Resources

Marc Auckland, CLL patient, and Lianne Palmer, CLL Clinical Nurse Specialist at Oxford University Hospitals NHSFT, discuss Marc's CLL journey from diagnosis through to treatment and beyond. They cover the challenges of living with CLL and the importance of good communication (15 minutes).

Found this useful? You might also be interested in:

Karen Stanley on the role of the chronic lymphocytic leukaemia (CLL) nurse in a multidisciplinary team (MDT)

Watch now

Karen Stanley on the evolving role of a chronic lymphocytic leukaemia (CLL) nurse

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

A chronic lymphocytic leukamia (CLL) patient journey with Lianne Palmer and Marc Auckland

Back to Resources

Marc Auckland, CLL patient, and Lianne Palmer, CLL Clinical Nurse Specialist at Oxford University Hospitals NHSFT, discuss Marc's CLL journey from diagnosis through to treatment and beyond. They cover the challenges of living with CLL and the importance of good communication (15 minutes).

Found this useful? You might also be interested in:

lymphocytic leukaemia (CLL) nurse in a multidisciplinary team (MDT)

Karen Stanley on the evolving role of a chronic lymphocytic leukaemia (CLL) nurse

Watch now

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

CALQUENCE®
acalabrutinib 100 mg tablets

Karen Stanley on the evolving role of a chronic lymphocytic leukaemia (CLL) nurse

Back to Resources



Advanced Nurse Practitioner Karen Stanley from Guys and St. Thomas' Hospital discusses how much CLL treatments have changed over the last 60 years, the ever-changing workload of the CLL Clinical Nurse Specialist, and how to help patients make informed treatment choices (5 minutes).

Found this useful? You might also be interested in:

Karen Stanley on the role of the chronic lymphocytic leukaemia (CLL) nurse in a multidisciplinary team (MDT)

Watch now

A chronic lymphocytic leukaemia (CLL) patient journey with Lianne Palmer and Marc Auckland

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Latest CLL News

Karen Stanley on the evolving role of a chronic lymphocytic leukaemia (CLL) nurse

Back to Resources

Advanced Nurse Practitioner Karen Stanley from Guys and St. Thomas' Hospital discusses how much CLL treatments have changed over the last 60 years, the ever-changing workload of the CLL Clinical Nurse Specialist, and how to help patients make informed treatment choices (5 minutes).

Found this useful? You might also be interested in:

Clinical Nurse Specialist in a chronic lymphocytic leukaemia (CLL) nurse in a multidisciplinary team (MDT)

A chronic lymphocytic leukamia (CLL) patient journey with Lianne Palmer and Marc Auckland

Watch now

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical support materials

CALQUENCE▼
acalabrutinib 100 mg tablets

CALQUENCE▼ (acalabrutinib) mode of action (MoA) video

Back to Resources

This animation describes the mode of action of acalabrutinib.

Found this useful? You might also be interested in:

CALQUENCE▼ (acalabrutinib) chronic lymphocytic leukaemia (CLL) Patient Information Booklet

Download

Match adjusted indirect comparison (MAIC) methodology explanation video

Download

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical support materials

CALQUENCE▼ (acalabrutinib) mode of action (MoA) video

Back to Resources

This animation describes the mode of action of acalabrutinib.

Found this useful? You might also be interested in:

CALQUENCE▼ (acalabrutinib) chronic lymphocytic leukaemia (CLL) Patient Information Booklet

Download

Match adjusted indirect comparison (MAIC) methodology explanation video

Download

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical support materials

CALQUENCE▼ acalabrutinib 100 mg tablets

CALQUENCE▼ (acalabrutinib) NICE reimbursement

Back to Resources



An algorithm detailing the NICE reimbursement criteria for CALQUENCE in previously untreated and previously treated CLL.

Found this useful? You might also be interested in:



Watch now

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical support materials

CALQUENCE▼ (acalabrutinib) NICE reimbursement

Back to Resources



An algorithm detailing the NICE reimbursement criteria for CALQUENCE in previously untreated and previously treated CLL.

Found this useful? You might also be interested in:

CALQUENCE▼ (acalabrutinib) mode of action (MoA) video

Watch now

Match adjusted indirect comparison (MAIC) methodology explanation video

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical support materials

CALQUENCE acalabrutinib 100 mg tablets

CALQUENCE Therapy Management Guide

Back to Resources



Developed in conjunction with Consultants and Nurses who treat CLL, this booklet outlines best practice and guidance for managing patients who are receiving CALQUENCE for CLL.

Found this useful? You might also be interested in:



Watch now

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical support materials

CALQUENCE Therapy Management Guide

Back to Resources



Developed in conjunction with Consultants and Nurses who treat CLL, this booklet outlines best practice and guidance for managing patients who are receiving CALQUENCE for CLL.

Found this useful? You might also be interested in:

The CLL Exchange: Guidance for managing complex chronic lymphocytic leukaemia (CLL) patients

Watch now

The CLL Exchange: Elevating the patient voice through MDT best practice

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical support materials

CALQUENCE▼
acalabrutinib 100 mg tablets

CALQUENCE▼ (acalabrutinib) Scottish Medicines Consortium (SMC) acceptance

Back to Resources

An algorithm detailing the SMC acceptance criteria for CALQUENCE in previously untreated and previously treated CLL.

Found this useful? You might also be interested in:

Watch now



Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical support materials

CALQUENCE▼ (acalabrutinib) Scottish Medicines Consortium (SMC) acceptance

Back to Resources



An algorithm detailing the SMC acceptance criteria for CALQUENCE in previously untreated and previously treated CLL.

Found this useful? You might also be interested in:

ELEVATE-TN
Clinical Trial 6 year data

Watch now

CALQUENCE▼ (acalabrutinib) mode of action (MoA) video

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical trial information

CALQUENCE ▼
acalabrutinib 100 mg tablets

ELEVATE-TN clinical trial summary

Back to Resources



A summary of the ELEVATE-TN trial, including 6 year follow up data: CALQUENCE with or without obinutuzumab vs. chlorambucil plus obinutuzumab for treatment-naïve CLL.

Found this useful? You might also be interested in:



View now



Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical trial information

ELEVATE-TN clinical trial summary

Back to Resources



A summary of the ELEVATE-TN trial, including 6 year follow up data: CALQUENCE with or without obinutuzumab vs. chlorambucil plus obinutuzumab for treatment-naïve CLL.

Found this useful? You might also be interested in:

ELEVATE-RR summary: CALQUENCE ▼ (acalabrutinib) vs ibrutinib

View now

The CLL Exchange: Practical tips from experts on BTKi selection in chronic lymphocytic leukamia (CLL)

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical trial information

CALQUENCE ▼
acalabrutinib 100 mg tablets

ELEVATE-RR summary: CALQUENCE ▼ (acalabrutinib) vs ibrutinib

Back to Resources



A summary of the ELEVATE-R/R trial: Calquence vs. ibrutinib in previously treated CLL.

Found this useful? You might also be interested in:

View now



Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting co[redacted]medical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical trial information

ELEVATE-RR summary: CALQUENCE▼(acalabrutinib) vs ibrutinib

Back to Resources



A summary of the ELEVATE-R/R trial: Calquence vs. ibrutinib in previously treated CLL.

Found this useful? You might also be interested in:

ELEVATE-TN clinical trial summary

View now

The CLL Exchange: Guidance for managing complex chronic lymphocytic leukaemia (CLL) patients

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical trial information

CALQUENCE▼
acalabrutinib 100 mg tablets

EPIC study: CALQUENCE▼ (acalabrutinib) in chronic lymphocytic leukaemia (CLL) real world data

Back to Resources



A summary of the outcomes of EPIC, a real world observational study for front-line CLL patients treated with acalabrutinib via the early access programme (interim analysis).

Found this useful? You might also be interested in:



Watch now

View now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical trial information

EPIC study: CALQUENCE▼ (acalabrutinib) in chronic lymphocytic leukaemia (CLL) real world data

Back to Resources



A summary of the outcomes of EPIC, a real world observational study for front-line CLL patients treated with acalabrutinib via the early access programme (interim analysis).

Found this useful? You might also be interested in:

EPIC real world data for front-line chronic lymphocytic leukaemia (CLL) patients treated with CALQUENCE▼(acalabrutinib)

Watch now

ELEVATE-TN clinical trial summary

View now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical trial information

CALQUENCE ▼
acalabrutinib 100 mg tablets

ASCEND clinical trial summary

Back to Resources



A summary of the ASCEND trial: CALQUENCE vs. idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory CLL.

Found this useful? You might also be interested in:

View now

View now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting medicalexcellence.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Clinical trial information

CALQUENCE
acalabrutinib 100 mg tablets

ASCEND clinical trial summary

Back to Resources



A summary of the ASCEND trial: CALQUENCE vs. idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory CLL.

Found this useful? You might also be interested in:

ELEVATE-RR summary: CALQUENCE ▼(acalabrutinib) vs ibrutinib

View now

ELEVATE-TN clinical trial summary

View now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Patient support materials

CALQUENCE▼ acalabrutinib 100 mg tablets

CALQUENCE▼(acalabrutinib) chronic lymphocytic leukaemia (CLL) Patient Information Booklet

Back to Resources

Download

Patient information booklet for patients prescribed CALQUENCE providing helpful information about CLL and CALQUENCE.

Found this useful? You might also be interested in:

Download

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244

Patient support materials

CALQUENCE▼ (acalabrutinib) chronic lymphocytic leukaemia (CLL) Patient Information Booklet

Back to Resources

Download

Patient information booklet for patients prescribed CALQUENCE providing helpful information about CLL and CALQUENCE.

Found this useful? You might also be interested in:

CALQUENCE Therapy Management Guide

Download

CALQUENCE▼ (acalabrutinib) mode of action (MoA) video

Watch now

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

May 2025 | GB-62244